ProKidney Corp. (PROK) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.91 (+6.11%), Market cap $0.49B, 52-week low–high $0.56 ~ $5.18.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartere
Financial statements, price targets, institutional (13F) holdings and related news for ProKidney Corp. are updated in real time on BlackAll Trade.
ProKidney Corp. trades at $1.91 (+6.11%). Real-time quotes and charts are available on BlackAll Trade.
ProKidney Corp. has a market cap of about $0.49B.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparence